Pyxis Oncology Inc. has announced revisions to the patient enrollment participants for its Phase 1 monotherapy clinical trial evaluating micvotabart pelidotin, also referred to as MICVO. This trial, designated as NCT05720117, is a first-in-human, open-label, multicenter study aimed at assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MICVO in individuals with advanced solid tumors. The study includes two parts: a dose escalation phase and a dose expansion phase. The company has confirmed its previous guidance regarding the estimated number of head and neck squamous cell carcinoma patients to be enrolled in the dose expansion phase of the study, as previously disclosed in its quarterly report. Results from this trial have not yet been presented and are anticipated in the future as the trial progresses.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。